45 citations
,
October 2009 in “Dermatology” Half of the patients treated with a specific drug for skin cancer experienced hair loss not related to the drug's dosage.
87 citations
,
March 2013 in “Expert Review of Anticancer Therapy” Afatinib often causes skin problems that need proactive management.
15 citations
,
November 2024 in “Journal of Advanced Research” miR-3606-3p reduces skin fibrosis by blocking key signaling pathways.
168 citations
,
August 2000 in “American Journal of Pathology” Fibromodulin might help reduce scarring if increased in adult wounds like in fetal skin that heals without scars.
7 citations
,
May 2007 in “PubMed” Women with androgenetic alopecia (AGA) are more insulin resistant than healthy women, with various insulin sensitivity indices being higher in the AGA group. An oral glucose tolerance test is suggested for women with AGA.
18 citations
,
March 2002 in “The journal of investigative dermatology/Journal of investigative dermatology” Estrogen increases blood vessel growth factor production, while testosterone blocks this increase.
6 citations
,
August 2014 in “Sri Lanka Journal of Diabetes Endocrinology and Metabolism” The FG score is better at detecting hyperandrogenism in PCOS patients than testosterone levels or FAI, but testosterone is the recommended test for diagnosis.
26 citations
,
August 2014 in “Genetic Testing and Molecular Biomarkers” High levels of TNF-α may contribute to obesity and insulin resistance in PCOS, but not due to the C850T genetic variation.
April 2026 in “Case Reports in Dermatology” Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.
January 2025 in “Biomedicines” High testosterone levels can harm fertility by disrupting the LIF signaling pathway in the uterus.
July 2025 in “Journal of Investigative Dermatology” Androgens reduce THY1 in skin cells, leading to less fat, more fibrosis, and worse healing in males.
71 citations
,
May 2024 in “New England Journal of Medicine” Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than medication for managing PCOS-related risks.
9 citations
,
August 2024 in “Tissue Engineering and Regenerative Medicine” Collagen-heparin-FGF2-VEGF scaffolds can improve skin healing.
23 citations
,
October 2018 in “Australasian Journal of Dermatology” The current understanding of frontal fibrosing alopecia involves immune, genetic, hormonal factors, and possibly environmental triggers, but more research is needed for effective treatments.
5 citations
,
April 2021 in “Journal of Academic Research in Medicine” FAI is a reliable marker for identifying and monitoring hyperandrogenism in obese adolescent females with PCOS.
May 2019 in “The Journal of Sexual Medicine” Flibanserin's effectiveness for low sexual desire in premenopausal women may vary based on hormone levels, with normal hormone levels showing better responses.
6 citations
,
November 1980 in “Clinical Endocrinology” Measuring plasma testosterone glucosiduronate is a reliable way to detect high male hormone levels in women.
44 citations
,
March 2008 in “European journal of endocrinology” Women with PCOS have lower ghrelin levels and a weaker response to sugar, which might affect their feeling of fullness and lead to overeating.
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than metformin for reducing type 2 diabetes risk.
37 citations
,
January 2009 in “Sexual Development” Fadrozole and Finasteride change frog sex ratios and cause intersex animals with altered gene expressions.
3 citations
,
May 2025 in “Frontiers in Pharmacology” Vismodegib can cause muscle spasms, taste changes, hair loss, fatigue, weight loss, and possibly new issues like skin cancer, dehydration, and swallowing problems, needing close monitoring.
60 citations
,
November 2009 in “General and Comparative Endocrinology” Fadrozole and finasteride change gene expression related to sex hormones and thyroid hormones in frog larvae development.
November 2010 in “Clin-Alert” Monitoring for adverse effects in clinical treatments is crucial.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
9 citations
,
October 2019 in “Dermatologic Therapy” Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
83 citations
,
January 2004 in “Pharmacology & Therapeutics” Adjusting neurosteroid levels may help reduce alcohol withdrawal symptoms.
17 citations
,
April 2006 in “Brain Research” 5α-reduced neurosteroids may help regulate glial cell differentiation.
November 2010 in “International Journal of Dermatology and Venereology” EGFR inhibitors can cause skin issues, and managing these is important for treatment success.
9 citations
,
April 2018 in “Biology of reproduction” Diet changes hormone levels in pregnant ewes by affecting metabolism, not placental synthesis.